Q1 EPS Estimate for Nektar Therapeutics Boosted by Analyst

Nektar Therapeutics (NASDAQ:NKTR) – Equities researchers at Zacks Research upped their Q1 2026 earnings estimates for shares of Nektar Therapeutics in a report issued on Tuesday, January 6th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of ($2.51) for the quarter, up from their previous estimate of ($2.59). The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics’ Q2 2026 earnings at ($2.63) EPS, Q3 2026 earnings at ($2.92) EPS, Q4 2026 earnings at ($4.20) EPS, FY2026 earnings at ($12.26) EPS, Q1 2027 earnings at ($3.25) EPS, Q2 2027 earnings at ($3.33) EPS, Q3 2027 earnings at ($3.83) EPS, Q4 2027 earnings at ($5.68) EPS and FY2027 earnings at ($16.09) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.85) by $1.00. The company had revenue of $11.79 million for the quarter, compared to analyst estimates of $10.20 million. Nektar Therapeutics had a negative net margin of 192.87% and a negative return on equity of 456.53%.

NKTR has been the subject of a number of other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Nektar Therapeutics in a research report on Monday, December 29th. Jefferies Financial Group reissued a “buy” rating on shares of Nektar Therapeutics in a research report on Wednesday, December 17th. HC Wainwright upped their price objective on shares of Nektar Therapeutics from $120.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. B. Riley lifted their target price on shares of Nektar Therapeutics from $85.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, September 23rd. Finally, Wall Street Zen downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Nektar Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $111.83.

Nektar Therapeutics Stock Down 4.2%

Shares of Nektar Therapeutics stock opened at $39.71 on Friday. Nektar Therapeutics has a 52 week low of $6.45 and a 52 week high of $66.92. The business has a 50 day moving average price of $52.41 and a 200-day moving average price of $43.72. The company has a market cap of $807.70 million, a PE ratio of -4.98 and a beta of 1.31.

Insider Transactions at Nektar Therapeutics

In related news, insider Jonathan Zalevsky sold 1,157 shares of Nektar Therapeutics stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $54.28, for a total value of $62,801.96. Following the completion of the sale, the insider owned 18,971 shares of the company’s stock, valued at approximately $1,029,745.88. This trade represents a 5.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Howard W. Robin sold 2,207 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $54.28, for a total value of $119,795.96. Following the completion of the sale, the chief executive officer owned 54,245 shares in the company, valued at $2,944,418.60. This represents a 3.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 3,994 shares of company stock worth $216,794. 5.25% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its stake in Nektar Therapeutics by 93.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 210 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of Nektar Therapeutics in the second quarter worth $39,000. Headlands Technologies LLC purchased a new position in shares of Nektar Therapeutics in the second quarter valued at $65,000. Integrated Wealth Concepts LLC bought a new stake in shares of Nektar Therapeutics during the 1st quarter valued at $68,000. Finally, Compass Wealth Management LLC bought a new stake in shares of Nektar Therapeutics during the 3rd quarter valued at $88,000. 75.88% of the stock is owned by institutional investors.

Nektar Therapeutics News Summary

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Zacks Research has revised several of its EPS forecasts for Nektar, trimming losses across multiple 2026–2027 quarters and lowering FY2026 and FY2027 loss projections (FY2027 now -$16.09 vs prior -$16.94). The revisions signal a modestly improved fundamental outlook from that analyst.
• Neutral Sentiment: The stock recently cleared its 200‑day moving average, a technical bullish sign that can attract momentum buyers but also prompt short-term profit‑taking from traders. Nektar Therapeutics (NASDAQ:NKTR) Shares Pass Above 200 Day Moving Average – Here’s What Happened Nektar Therapeutics (NASDAQ:NKTR) Stock Passes Above Two Hundred Day Moving Average – Time to Sell?
• Negative Sentiment: Pomerantz LLP has launched an investor investigation into Nektar, which introduces litigation risk and uncertainty that typically weighs on biotech shares until resolved or clarified. That legal development is likely the main driver putting downward pressure on the stock today. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics – NKTR

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.